Tetravalent Dengue Vaccine (TDV)

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

3 competitors in Dengue Fever

#DrugCompanyPhaseTrials

1

Relenza

GGlaxo Dba Glaxosmithkline

Phase 2

12

Tetravalent Dengue Vaccine (TDV)

Takeda

Phase 3

13

Butantan - DV

BButantan Institute

Phase 3

14

Anti-D

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity3 trials

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Completed·Takeda·Phase 3·NCT03771963·200 enrolled

Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Completed·Takeda·Phase 3·NCT02747927·20,099 enrolled

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)

Completed·Takeda·Phase 3·NCT03341637·400 enrolled

Dengue Disease1 trial

Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease

Completed·UU.S. Army Medical Research and Development Command·Phase 1·NCT01502358·40 enrolled

Dengue Fever1 trial

A Randomized, Double-Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of a New Formulation of Tetravalent Dengue Vaccine (TDV) Versus the Current Formulation of TDV in Healthy Adults (Aged 18-60 Years) in a Non-Endemic Area for Dengue

Active, not recruiting·Takeda·Phase 3·NCT07047521·496 enrolled

Details

Drug Info

Related News